Melanocortin agonist
An FDA-approved medication that acts on desire in the brain rather than blood flow in the body.
PT-141, approved as bremelanotide and marketed as Vyleesi, is one of the few compounds discussed in peptide circles that is genuinely an approved drug — FDA-cleared in 2019 for hypoactive sexual desire disorder in premenopausal women. It is mechanistically unlike Viagra or Cialis, and that difference is the entire point of it.
Erectile medications work on plumbing — they improve blood flow to tissue. PT-141 works upstream, in the brain, on the melanocortin system that governs desire itself. That is why it can help in situations where blood-flow drugs do nothing, and why it works differently: not on demand in the mechanical sense, but on wanting.
Bremelanotide is a synthetic analog of alpha-MSH that activates melanocortin receptors, principally MC4R and MC3R, in the central nervous system. Receptor activation in the hypothalamus and medial preoptic area modulates dopaminergic signaling in pathways governing sexual motivation. It does not act on the vascular or nitric oxide pathways targeted by PDE5 inhibitors. Administered subcutaneously roughly 45 minutes before anticipated activity.
Onset is in the range of 45 minutes to a couple of hours. The effect is on desire and arousal rather than mechanical function, which some people find harder to evaluate than an erection. Nausea is common enough that it is worth planning around — it affected a substantial minority in the trials.
Every page on this site includes this section. If a source only tells you what something does, you are reading marketing.
Nausea is the most common adverse effect and was frequent in trials. It raises blood pressure transiently and lowers heart rate, which makes it inappropriate for anyone with uncontrolled hypertension or significant cardiovascular disease. Skin darkening can occur with repeated use given the melanocortin mechanism. Approved use is limited to a maximum of eight doses per month. Not appropriate during pregnancy.
An FDA-approved version exists — Vyleesi — which is the appropriate route for anyone who qualifies. Research-grade supply of an approved drug is a meaningfully different proposition, and worth thinking about before defaulting to it.
Yes, as bremelanotide (Vyleesi), for hypoactive sexual desire disorder in premenopausal women. Other uses are off-label.
Entirely different mechanism. PDE5 inhibitors improve blood flow; PT-141 acts on melanocortin pathways in the brain governing desire.
Frequently. It was the most common adverse effect in clinical trials and is worth anticipating.
General education only goes so far. If you want help deciding whether this is relevant to your goals, history, and current labs, schedule a consultation with the Bearing team.
Request a Consultation